Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

Inclusion Criteria:

- male or female ages 18 and up

- utilizing a regimen of at least two injections daily of insulin and at least two
injections daily of Symlin

- able to understand and sign an informed consent form and HIPPA form

- agrees to all study visits and procedures

- HbA1c between >6.5 and <9.0 (inclusive)

Exclusion Criteria:

- history or current diagnosis of chronic disease which in the view of the PI would
interfere with adequate involvement in and completion of the requirements of the study

- history of malignancy with in the last five years of study entry (other than basal
cell carcinoma)

- current use of any drugs that alter gastrointestinal motility (e.g., anticholinergic
agents such as atropine), agents that slow intestinal absorption of nutrients (e.g.
a-glucosidase inhibitors) or promotility agents (e.g. metachlopromide)

- any contraindication of Symlin or I-PORT according to the package labeling

- are female and pregnant, lactating or planning to become pregnant during the duration
of the trial

- are poorly compliant with their current insulin and/or Symlin regimen, as defined by
their HCP

- has history of known hypersensitivity to plastics or polymers

- treatment with any investigational drug within one month prior to enrollment

- myocardial infarction or stroke within six months prior to screening

- initiated use of Symlin pen or any Insulin pen in lieu of a vial in last 4 weeks (pen
use is okay as long as they have been using it for at least 4 weeks prior to screening
visit)

- female subjects of childbearing potential practicing inadequate birth control
(adequate birth control is defined as using oral contraceptives, double barrier
methods, Intrauterine devices, surgical sterilization or vasectomized partner)

- have confirmed diagnosis of gastroparesis

- have hypoglycemia unawareness